Preoperative Radiation Therapy and Immediate Breast Reconstruction

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Breast Neoplasms, Breast Carcinoma, Breast Adenocarcinoma, Cancer, Neoplasm

In brief

The goal of this phase III randomized controlled trial (PRADAIIBE) is to assess if preoperative radiation therapy (Preop-RT) combined with immediate breast reconstruction (IBR) can safely improve both aesthetic and quality of life outcomes in breast cancer patients, compared to the standard of care (SoC) therapy consisting of post-mastectomy radiation therapy (PMRT) and delayed/immediate breast reconstruction, in a population of breast cancer patients with an indication of mastectomy and PMRT. The following hypotheses and outcomes will be assessed at the primary endpoint of 1 year of follow-up: * Efficacy: Does Preop-RT+IBR lead to a higher BREAST-Q satisfaction with breasts score (primary endpoint), EQ-5D-5L VAS score , EQ-5D-5L Index score, AIS-Total Aesthetic Score, or a shorter treatment duration compared to SoC? * Safety: Does Preop-RT+IBR lead to an increase in adverse events (general or surgical), a lower rate of pathologic Complete Response (pCR), or worse survival outcomes compared to SoC? \[Note: this study was not powered as a non-inferiority trial, all outcomes will be pooled internationally with parallel studies\] Eligible and consenting participants will undergo screening and baseline assessments. They will then be randomised between experimental (Preop-RT+IBR) and control (SoC) groups, in a 1:1 stratified variable block size design. Follow-up will take place at 3 months, 1, 2, 5, and 10 years after the last study treatment. At baseline and during each follow-up visit each participant will complete the Breast Q 'satisfaction with breasts' and EQ-5D-5L scales, photographs will be taken. During follow-up pCR will be assessed if applicable, adverse events will be registered, and oncological follow-up will be recorded.

Key facts

Study ID: NCT06739655
Run by: Cancer Research Antwerp
People needed: 180
Starts: 2025-02-20
Expected to finish: 2038-02-20
Last updated by the study team: 2026-02-04

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

In order to be eligible to participate in this study, a participant must meet all of the following criteria:
Women ≥18 years with histopathologically confirmed breast cancer who:
a. require SSM/NSM for any reason (e.g. extensive disease)
b. require postoperative radiation therapy of at least the chest wall
c. have a wish for a breast reconstruction
An Eastern Cooperative Oncology Group (ECOG) performance status grade ≤ 2
Participant is able and willing to provide written informed consent, which includes compliance with and ability to undergo all study procedures, and attend the scheduled follow-up visit(s) per protocol.

You may not qualify if…

A potential participant who meets any of the following criteria will be excluded from participation in this study:
A previous history of breast cancer or irradiation of the chest wall for any other indication, on the other side (ipsilateral). A bilateral SSM/NSM + reconstruction (e.g. in case of a contralateral prophylactic SSM/NSM), or previous contralateral breast cancer disease/treatment, do not fall under this criterium and are thus allowed.
Collagen synthesis disease
Ongoing pregnancy
Actively breastfeeding
Smoking at time of inclusion (a history of smoking is allowed but needs to be registered in the eCRF). No interval between smoking cessation and study inclusion is defined, but the reconstructive surgeon needs to be willing to operate the patient using autologous tissue transfer. This generally translates to a smoking cessation of >3months preoperatively.
BMI > 35 kg/m2
cT4d tumour, metastatic disease or any reason making SSM/NSM not indicated

Where it is running

Universitair Ziekenhuis Antwerpen (UZA) — Edegem, Antwerpen, Belgium (enrolling)
Ziekenhuis aan de stroom — Wilrijk, Antwerpen, Belgium (enrolling)
CHU Namur — Namur, Namur, Belgium (enrolling)
AZ Groeninge — Kortrijk, West Vlaanderen, Belgium (enrolling)
AZ Klina — Brasschaat, Antwerp, Belgium
Universitair Ziekenhuis Gent (UZGent) — Ghent, Oost Vlaanderen, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.